Literature DB >> 27103634

Proteomic Analysis of the Developmental Trajectory of Human Hepatic Membrane Transporter Proteins in the First Three Months of Life.

Miriam G Mooij1, Evita van de Steeg1, Joost van Rosmalen1, Jonathan D Windster1, Barbara A E de Koning1, Wouter H J Vaes1, Bianca D van Groen1, Dick Tibboel1, Heleen M Wortelboer1, Saskia N de Wildt2.   

Abstract

Human hepatic membrane-embedded transporter proteins are involved in trafficking endogenous and exogenous substrates. Even though impact of transporters on pharmacokinetics is recognized, little is known on maturation of transporter protein expression levels, especially during early life. We aimed to study the protein expression of 10 transporters in liver tissue from fetuses, infants, and adults. Transporter protein expression levels [ATP-binding cassette transporter (ABC)B1, ABCG2, ABCC2, ABCC3, bile salt efflux pump, glucose transporter 1, monocarboxylate transporter 1, organic anion transporter polypeptide (OATP)1B1, OATP2B1, and organic cation/carnitine transporter 2) were quantified using ultraperformance liquid chromatography tandem mass spectrometry in snap-frozen postmortem fetal, infant, and adult liver samples. Protein expression was quantified in isolated crude membrane fractions. The possible association between postnatal and postmenstrual age versus protein expression was studied. We studied 25 liver samples, as follows: 10 fetal [median gestational age 23.2 wk (range 16.4-37.9)], 12 infantile [gestational age at birth 35.1 wk (27.1-41.0), postnatal age 1 wk (0-11.4)], and 3 adult. The relationship of protein expression with age was explored by comparing age groups. Correlating age within the fetal/infant age group suggested four specific protein expression patterns, as follows: stable, low to high, high to low, and low-high-low. The impact of growth and development on human membrane transporter protein expression is transporter-dependent. The suggested age-related differences in transporter protein expression may aid our understanding of normal growth and development, and also may impact the disposition of substrate drugs in neonates and young infants.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27103634     DOI: 10.1124/dmd.115.068577

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  11 in total

Review 1.  Trafficking and other regulatory mechanisms for organic anion transporting polypeptides and organic anion transporters that modulate cellular drug and xenobiotic influx and that are dysregulated in disease.

Authors:  Michael Murray; Fanfan Zhou
Journal:  Br J Pharmacol       Date:  2017-04-24       Impact factor: 8.739

2.  RNA Sequencing Reveals Age and Species Differences of Constitutive Androstane Receptor-Targeted Drug-Processing Genes in the Liver.

Authors:  Sunny Lihua Cheng; Theo K Bammler; Julia Yue Cui
Journal:  Drug Metab Dispos       Date:  2017-02-23       Impact factor: 3.922

3.  The Promises of Quantitative Proteomics in Precision Medicine.

Authors:  Bhagwat Prasad; Marc Vrana; Aanchal Mehrotra; Katherine Johnson; Deepak Kumar Bhatt
Journal:  J Pharm Sci       Date:  2016-12-08       Impact factor: 3.534

Review 4.  Incorporating Ontogeny in Physiologically Based Pharmacokinetic Modeling to Improve Pediatric Drug Development: What We Know About Developmental Changes in Membrane Transporters.

Authors:  Kit Wun Kathy Cheung; Bianca D van Groen; Gilbert J Burckart; Lei Zhang; Saskia N de Wildt; Shiew-Mei Huang
Journal:  J Clin Pharmacol       Date:  2019-09       Impact factor: 3.126

5.  Ontogeny of Hepatic Drug Transporters as Quantified by LC-MS/MS Proteomics.

Authors:  B Prasad; A Gaedigk; M Vrana; R Gaedigk; J S Leeder; L Salphati; X Chu; G Xiao; Ceca Hop; R Evers; L Gan; J D Unadkat
Journal:  Clin Pharmacol Ther       Date:  2016-08-13       Impact factor: 6.875

6.  Lobular Distribution and Variability in Hepatic ATP Binding Cassette Protein B1 (ABCB1, P-gp): Ontogenetic Differences and Potential for Toxicity.

Authors:  Ngu Njei Abanda; Zoe Riches; Abby C Collier
Journal:  Pharmaceutics       Date:  2017-02-17       Impact factor: 6.321

7.  A Comprehensive Analysis of Ontogeny of Renal Drug Transporters: mRNA Analyses, Quantitative Proteomics, and Localization.

Authors:  Kit Wun Kathy Cheung; Bianca D van Groen; Edwin Spaans; Marjolein D van Borselen; Adrianus C J M de Bruijn; Ytje Simons-Oosterhuis; Dick Tibboel; Janneke N Samsom; Robert M Verdijk; Bart Smeets; Lei Zhang; Shiew-Mei Huang; Kathleen M Giacomini; Saskia N de Wildt
Journal:  Clin Pharmacol Ther       Date:  2019-07-03       Impact factor: 6.875

8.  Proof of Concept: First Pediatric [14 C]microtracer Study to Create Metabolite Profiles of Midazolam.

Authors:  Bianca D van Groen; Esther van Duijn; Arjan de Vries; Miriam G Mooij; Dick Tibboel; Wouter H J Vaes; Saskia N de Wildt
Journal:  Clin Pharmacol Ther       Date:  2020-06-27       Impact factor: 6.875

Review 9.  Physiologically Based Pharmacokinetic Models Are Effective Support for Pediatric Drug Development.

Authors:  Kefei Wang; Kun Jiang; Xiaoyi Wei; Yulan Li; Tiejie Wang; Yang Song
Journal:  AAPS PharmSciTech       Date:  2021-07-26       Impact factor: 3.246

10.  Mass spectrometry-based abundance atlas of ABC transporters in human liver, gut, kidney, brain and skin.

Authors:  Zubida M Al-Majdoub; Brahim Achour; Narciso Couto; Martyn Howard; Yasmine Elmorsi; Daniel Scotcher; Sarah Alrubia; Eman El-Khateeb; Areti-Maria Vasilogianni; Noura Alohali; Sibylle Neuhoff; Lutz Schmitt; Amin Rostami-Hodjegan; Jill Barber
Journal:  FEBS Lett       Date:  2020-12-03       Impact factor: 3.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.